Not yet recruitingInterventionalPhase 1Phase 2Last updated Aug 7, 2026

A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy

An Open-label, Single-arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Equecabtagene Autoleucel Injection (Eque-cel) in Subjects With Immune-mediated Necrotizing Myopathy

Overview

ClinicalTrials.gov ID: NCT07752264
Lead Sponsor: Nanjing IASO Biotechnology Co., Ltd.INDUSTRY
Brief Summary: This is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 15, 2026Estimated
Primary Completion Date: Aug 15, 2030Estimated
Completion Date: Aug 15, 2043Estimated

Study Record Dates

First Submitted: Aug 3, 2026
First Submitted that Met QC Criteria: Aug 3, 2026
First Posted: Aug 7, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 3, 2026
Last Update Posted: Aug 7, 2026Actual
Last Verified: Aug 2026

NCT07510100Not yet recruiting

Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT06464991Recruiting

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

NCT06902844Recruiting

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

NCT07028970Recruiting

Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

NCT06626919Recruiting

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

NCT07055724Not yet recruiting

Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis